(Q28259304)

Influenza A/H5N1 virus infection in humans in Cambodia

31 March 2020

1 reference

Prophylaxis and treatment of influenza

31 March 2020

1 reference

Rimantadine: A Clinical Perspective

31 March 2020

1 reference

Influenza virus M2 protein has ion channel activity

31 March 2020

1 reference

Pandemic influenza: its origin and control.

31 March 2020

1 reference

Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin

31 March 2020

1 reference

Functional balance between haemagglutinin and neuraminidase in influenza virus infections

31 March 2020

1 reference

Influenza A pandemics of the 20th century with special reference to 1918: virology, pathology and epidemiology.

31 March 2020

1 reference

Influenza virus strains selectively recognize sialyloligosaccharides on human respiratory epithelium; the role of the host cell in selection of hemagglutinin receptor specificity

31 March 2020

1 reference

Sialic acid species as a determinant of the host range of influenza A viruses

31 March 2020

1 reference

Natural and synthetic sialic acid-containing inhibitors of influenza virus receptor binding

31 March 2020

1 reference

Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution

31 March 2020

1 reference

Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid

31 March 2020

1 reference

Crystallographic detection of a second ligand binding site in influenza virus hemagglutinin

31 March 2020

1 reference

Crystal structures of influenza virus hemagglutinin in complex with high-affinity receptor analogs

31 March 2020

1 reference

Characterization of temperature sensitive influenza virus mutants defective in neuraminidase

31 March 2020

1 reference

Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution

31 March 2020

1 reference

Structure of the catalytic and antigenic sites in influenza virus neuraminidase

31 March 2020

1 reference

Structural studies of the resistance of influenza virus neuramindase to inhibitors

31 March 2020

1 reference

Neuraminidase inhibitors as antivirals

31 March 2020

1 reference

Rational design of potent sialidase-based inhibitors of influenza virus replication

31 March 2020

1 reference

Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity

31 March 2020

1 reference

Site-directed mutation of the active site of influenza neuraminidase and implications for the catalytic mechanism.

31 March 2020

1 reference

Evidence for a sialosyl cation transition-state complex in the reaction of sialidase from influenza virus

31 March 2020

1 reference

Effect of substrate aglycon on enzyme mechanism in the reaction of sialidase from influenza virus

31 March 2020

1 reference

The interaction of substrate-related ketals with bacterial and viral neuraminidases

31 March 2020

1 reference

Influenza virus neuraminidase: structure, antibodies, and inhibitors

31 March 2020

1 reference

Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase

31 March 2020

1 reference

Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis

31 March 2020

1 reference

Recent strategies in the search for new anti-influenza therapies

31 March 2020

1 reference

Inhibition of influenza and parainfluenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA).

31 March 2020

1 reference

Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action

31 March 2020

1 reference

Uptake, metabolism and excretion of orally and intravenously administered, double-labeled N-glycoloylneuraminic acid and single-labeled 2-deoxy-2,3-dehydro-N-acetylneuraminic acid in mouse and rat

31 March 2020

1 reference

A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs

31 March 2020

1 reference

A computational procedure for determining energetically favorable binding sites on biologically important macromolecules

31 March 2020

1 reference

The synthesis of 2,3-didehydro-2,4-dideoxy-4-guanidinyl-N-acetylneuraminic acid: a potent influenza virus sialidase inhibitor

31 March 2020

1 reference

Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid modified at the C-4 position

31 March 2020

1 reference

4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro

31 March 2020

1 reference

A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir.

31 March 2020

1 reference

Unsaturated N-acetyl- D-glucosaminuronic acid glycosides as inhibitors of influenza virus sialidase.

31 March 2020

1 reference

BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design

31 March 2020

1 reference

Enantioselective synthesis of antiinfluenza compound A-315675.

31 March 2020

1 reference

Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors

31 March 2020

1 reference

Avian flu: isolation of drug-resistant H5N1 virus.

31 March 2020

1 reference

Oseltamivir and delirious behavior in children with influenza

31 March 2020

1 reference

The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design.

31 March 2020

1 reference

Antiviral therapy targeting viral polymerase

31 March 2020

1 reference

Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention.

31 March 2020

1 reference

Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants

31 March 2020

1 reference

Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic.

31 March 2020

1 reference

Influenza vaccine: the challenge of antigenic drift.

31 March 2020

1 reference

The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor

31 March 2020

1 reference

Influenza B virus neuraminidase can synthesize its own inhibitor

31 March 2020

1 reference

Dissection of nucleophilic and acid-base catalysis in glycosidases

31 March 2020

1 reference

LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions

31 March 2020

1 reference

Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding

31 March 2020

1 reference